Skip to main content
. 2013 Aug 6;109(5):1252–1263. doi: 10.1038/bjc.2013.439

Figure 6.

Figure 6

Impact of Pyk2[pY881] expression on overall survival of NSCLC patients. (A) Overall survival curves show that patients with high Pyk2[pY881] expression have short survival time by analysing 128 primary NSCLC tissues (P<0.001). (B) Patients with high Pyk2[pY881] expression show poor overall survival by analysing 47 matched metastatic lymph node tissues (P=0.005). (C, D) In the squamous carcinoma subtype, patients with high Pyk2[pY881] expression have poor overall survival (P=0.006). In the adenocarcinoma subtype, patients with high Pyk2[pY881] expression show short overall survival time (P<0.001). The Pyk2[pY881] low expression: score ⩽3; high expression: score ⩾4.